Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review
Open Access
- 7 February 2017
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (2) , 341
Abstract
The new drugs delamanid and bedaquiline are increasingly being used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB). The World Health Organization, based on lack of evidence, recommends their use under specific conditions and not in combination. No systematic review has yet evaluated the efficacy, safety, and tolerability of delamanid and bedaquiline used in combination. A search of peer-reviewed, scientific evidence was carried out, aimed at evaluating the efficacy/effectiveness, safety, and tolerability of delamanid and bedaquiline-containing regimens in individuals with pulmonary/extrapulmonary disease, which were bacteriologically confirmed as M/XDR-TB. We used PubMed to identify any relevant manuscripts in English up to the 23 December 2016, excluding editorials and reviews. Three out of 75 manuscripts retrieved satisfied the inclusion criteria, whilst 72 were excluded for dealing with only one drug (three studies), being recommendations (one study) or identifying need for their use (one study), focusing on drug resistance aspects (six studies) or being generic reviews/other studies (61 papers). The studies retrieved reported two XDR-TB cases observed for six months and achieving consistent sputum smear and culture conversion. Case 2 experienced a short break of bedaquiline, which was re-started after introducing verapamil. After a transient and symptom-free increase of the QT interval from week 5 to 17, it then decreased below the 500 ms threshold.Keywords
This publication has 41 references indexed in Scilit:
- Linezolid for Treatment of Chronic Extensively Drug-Resistant TuberculosisNew England Journal of Medicine, 2012
- Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosisEuropean Respiratory Journal, 2012
- Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TBEuropean Respiratory Journal, 2012
- Delamanid for Multidrug-Resistant Pulmonary TuberculosisNew England Journal of Medicine, 2012
- Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysisEuropean Respiratory Journal, 2012
- On linezolid efficacy and tolerabilityEuropean Respiratory Journal, 2012
- Tuberculosis: cost of illness in GermanyEuropean Respiratory Journal, 2012
- Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosisEuropean Respiratory Journal, 2011
- WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 updateEuropean Respiratory Journal, 2011
- The Diarylquinoline TMC207 for Multidrug-Resistant TuberculosisNew England Journal of Medicine, 2009